Top SEHK Growth Companies With High Insider Ownership In October 2024
In This Article:
As global markets experience varied economic shifts, with U.S. stocks reaching new highs and Chinese equities facing declines, the Hong Kong market remains a focal point for investors seeking growth opportunities amidst these fluctuations. In this context, identifying companies with high insider ownership can be particularly insightful, as such alignment often signals confidence in a company's potential to navigate current economic conditions effectively.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
| Name | Insider Ownership | Earnings Growth |
| Laopu Gold (SEHK:6181) | 36.4% | 33.2% |
| Akeso (SEHK:9926) | 20.5% | 53% |
| Fenbi (SEHK:2469) | 33.1% | 22.4% |
| Xiamen Yan Palace Bird's Nest Industry (SEHK:1497) | 26.7% | 23.8% |
| Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.8% | 69.8% |
| Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
| DPC Dash (SEHK:1405) | 38.1% | 104.2% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 109.2% |
| Beijing Airdoc Technology (SEHK:2251) | 29.1% | 93.4% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 69.7% |
We'll examine a selection from our screener results.
ESR Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ESR Group Limited operates in logistics real estate development, leasing, and management across various regions including Hong Kong, China, Japan, South Korea, Australia, New Zealand, Southeast Asia, India, Europe and internationally with a market cap of HK$52.05 billion.
Operations: The company's revenue segments include Fund Management at $628 million, New Economy Development at $113.33 million, and Investment at -$106.44 million.
Insider Ownership: 13%
Revenue Growth Forecast: 16.4% p.a.
ESR Group is poised for growth, with revenue expected to increase by 16.4% annually, outpacing the Hong Kong market average. Despite recent financial setbacks, including a US$218.72 million net loss for H1 2024 due to non-cash asset revaluations, the company is forecasted to return to profitability within three years. The transition of leadership from Jeffrey Perlman to Brett Krause may influence strategic direction but hasn't led to significant insider trading activity recently.
-
Click here and access our complete growth analysis report to understand the dynamics of ESR Group.
-
The valuation report we've compiled suggests that ESR Group's current price could be inflated.
Biocytogen Pharmaceuticals (Beijing)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of antibody-based drugs across China, the United States, and internationally, with a market cap of HK$2.98 billion.